Información del producto
- (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-3-pyrrolidinecarboxylic acid
- 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-, (2R,3R,4S)-
- 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-, [2R-(2α,3β,4α)]-
- 3-Pyrrolidinecarboxylicacid,4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-,[2R-(2a,3b,4a)]-
- A 192621
- A 192621.1
A-192621 is a new drug that inhibits the activity of angiotensin II type 1 (AT1) receptors. This drug has been shown to significantly reduce systolic blood pressure in rats and to decrease cardiac hypertrophy in mice. A-192621 also reduces the glomerular filtration rate, which may be due to its ability to inhibit tubulointerstitial injury. The pharmacokinetic properties of this drug have been studied in detail and it has been shown that it can cross the blood-brain barrier and bind to basic fibroblast cells. A-192621 also shows an anti-diabetic effect by specifically inhibiting the production of natriuretic peptides.
Propiedades químicas
Consulta técnica sobre: 3D-VHA52954 A-192621
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
